



**Incidence of Cytomegalovirus IgG antibodies and the
role of Matrix Metalloproteinase-13 (MMP-13)-as a
novel tumor marker- for Diagnosis of Breast Cancer in
Egyptian Females**

*A Thesis Submitted for the Degree of Ph.D in Science
(Microbiology)*

BY

Aliaa Mohamed Seif Elden Abd Elkader

MSc in Microbiology (2014)

Supervised by

Professor/ Ahmed Barakat Barakat

Professor of Microbiology

Faculty of Science - Ain Shams University

Professor/ Nahla Mohamed Zakaria Yousef

Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

Doctor/ Dina Aly Mohamed Aly

Assistant Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

Doctor/ Omar Alfarouk Rabiee

Lecturer of Microbiology

Faculty of Science - Ain Shams University

Microbiology Department

Faculty of Science

Ain Shams University

(2019)



**Approval sheet
(Ph.D.Thesis)**

Name: Aliaa Mohamed Seif Elden Abd Elkader

Title: Incidence of Cytomegalovirus IgG antibodies and the role of Matrix Metalloproteinase-13 (MMP-13)-as a novel tumor marker- for Diagnosis of Breast Cancer in Egyptian Females

Supervisions committee:

Prof Dr/ Ahmed Barakat Barakat

Professor of Microbiology-Faculty of Science -Ain Shams University

Prof Dr/ Nahla Mohamed Zakaria Yousef

Professor of Clinical Pathology-Faculty of Medicine - Ain Shams University

Dr/ Dina Aly Mohamed Aly

Assistant Professor of Clinical Pathology-Faculty of Medicine - Ain Shams University

Dr/ Omar Alfarouk Rabiee

Lecturer of Microbiology-Faculty of Science - Ain Shams University

Examination committee:

Prof Dr/ Neveen Ahmed Abdulhafeez

Professor of Clinical Pathology-Faculty of Medicine - Banha University

Prof Dr: Aly Fahmy Mohamed El-Sayed

Head of Research & Development Sector, Holding Company For Production of Vaccines, Sera And Drugs (VACSERA)

Prof Dr/ Ahmed Barakat Barakat

Professor of Microbiology-Faculty of Science -Ain Shams University

Prof Dr/ Nahla Mohamed Zakaria Yousef

Professor of Clinical Pathology-Faculty of Medicine - Ain Shams University

(2019)

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ
لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ
أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية 32

Declaration

I declare that this thesis has been composed by me and that the work of which is a record has done by me. It has not been submitted for a degree at this or any other university.

Aliaa Mohamed Seif Elden Abd Elkader

Dedication

To my family

My great father and my kind mother

*Thank you for supporting me with kindness, patience and
love*

Acknowledgement

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Professor/ Ahmed Barakat Barakat**, Professor of Microbiology, Faculty of Science, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Professor/ Nahla Mohamed Zakaria**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I am deeply thankful to **Dr/ Dina Aly Mohamed**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance through out this work.*

*I wish to introduce my deep respect and thanks to **Dr/ Omar Alfarouk Rabiee**, Lecturer of Microbiology, Faculty of Science, Ain Shams University, for his kindness, supervision and cooperation in this work.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all the patients who participated in this study.

List of Contents

Title	Page No.
List of Abbreviations.....	I
List of Tables.....	III
List of Figures.....	IV
Chapter I	
Introduction.....	1
Aim of the Work.....	3
Chapter II	
Review of literature	
- Section A: Breast cancer.....	4
A. Signs and symptoms.....	4
B. Risk factors.....	5
C. Screening and Diagnosis.....	6
D. Clinical stages.....	7
E. Management.....	8
F. Prevention.....	9
-Fibroadenoma.....	11
- Section B: Matrix Metalloproteinases	12
- Types of Matrix Metalloproteinases.....	13
- Matrix Metalloproteinase-13 (MMP-13).....	15
A. MMP-13 Gene	15

B. Expression of MMP-13.....	16
C. Activation of MMP-13.....	16
D. MMP-13 function.....	17
E. Role of MMP-13 in pathological conditions.....	17
- Section C: Cytomegalovirus.....	18

Chapter III

Subjects and Methods.....	22
I. Subjects.....	22
II. Methods.....	22
A. Collection of blood samples for laboratory tests.....	23
B. Measurment of CA15.3 levels.....	23
C. Assessment of cytomegalovirus (CMV) IgG.....	24
D. Measurment of Human MMP-13 levels.....	28
E. Statistical methodology.....	32

Chapter IV

Results.....	34
• Comparative statistical analysis between the three studied groups regarding MMP-13 and CA15.3 using Kruskal-Wallis test.....	35
• Comparative statistical analysis between group I and group II using Wilcoxn Rank Sum test.....	36
• Comparative statistical analysis between group I and group III using Wilcoxn Rank Sum test.....	37
• Comparative statistical analysis between group II and group III using Wilcoxn Rank Sum test.....	38
• Correlation between MMP-13 and CA15.3 in the different studied groups.....	38

- CMV IgG status in the three studied groups.....39
- Diagnostic performance of MMP-13 levels.....40
- Diagnostic performance of CA15.3 levels.....41

Chapter V

Discussion.....	43
------------------------	-----------

Chapter VI

Summary, Conclusion and Recommendations	52
--	-----------

Chapter VII

References....	55
-----------------------	-----------

Arabic Summary.....	1
----------------------------	----------

List of Abbreviations

ASCO	American Society of Clinical Oncology
AUC	Area under the curve
BKV	Polyomavirus hominis1
CA15.3	Carbohydrate antigen15.3
CA 27.29	Carbohydrate antigen 27.29
CEA	Carcino-embryonic antigen
CMV	Cytomegalovirus
CT Scan	Computerized Tomography Scan
EBV	Epstein–Barr virus
ECLIA	Electro-chemiluminescence immunoassay
ECM	Extracellular matrix
ELISA	Enzyme linked immunosorbent assay
ER-	Estrogen receptor-negative
ER+	Estrogen receptors positive
FNAC	Fine needle aspiration and cytology
HBV	Hepatits B virus
HCMV	Human Cytomegalovirus
HCV	Hepatits C virus
HCL	Hydrochloric acid
HHV-5	Human herpesvirus 5
HIV	Human immunodeficiency virus

HMTV/MMTV	Human Mammary Tumor Virus/ Mouse mammary tumor virus
HPV	Human papilloma virus
HRP-conjugate	Horseradish peroxidase
HTLV-1	Human T-cell lymphotropic <i>virus</i>
JCV	John Cunningham virus
KSHV	Kaposi's Sarcoma-associated Herpes <i>Virus</i>
MCV	Markel cell polyomavirus
MMPs	Matrix metalloproteinases
MMP-13	Matrix Metalloproteinase-13
MUC	Mucin
PBS	Phosphate buffer saline
PET scans	Positron emission tomography
PR+	Progesterone receptors positive
ROC	Receiver operating characteristic
SPSS	Statistical Package for the Social Sciences
SV40	Simian <i>virus</i> 40
TMB reagent	3,3',5,5'-Tetramethylbenzidine
TNM system	Tumor, lymph node, metastasis scoring system

List of Tables

Table No.	Title	Page
Table (a):	Types of Matrix Metalloproteinases	13
Table (1):	Comparative statistical analysis between the three studied groups regarding MMP-13 and CA15.3 using Kruskal-Wallis test	35
Table (2):	Comparative statistical analysis between group I and group II using Wilcoxon Rank Sum test	36
Table (3):	Comparative statistical analysis between group I and group III using Wilcoxon Rank Sum test	37
Table (4):	Comparative statistical analysis between group II and group III using Wilcoxon Rank Sum test	38
Table (5):	Correlation between MMP-13 and CA15.3	38
Table (6):	CMV IgG status in the three studied groups	39
Table (7):	Diagnostic performance of MMP-13 levels	40
Table (8):	Diagnostic performance of CA15.3 levels	41

List of Figures

Figure No.	Title	Page
Fig. (a):	Structural Domains of MMPs adopted from	15
Fig. (b):	Cytomegalovirus	18
Fig. (c):	Detection of CA15.3 by ECLIA	24
Fig. (1):	Median levels of MMP-13 in the three studied groups	35
Fig. (2):	Median levels of CA15-3 in the three studied groups	36
Fig. (3):	ROC curve analysis showing the diagnostic performance ofMMP-13 for discriminating patient groups from each other	40
Fig. (4):	ROC curve analysis showing the diagnostic performance of CA15.3 for discriminating patient groups from each other	42

Aim of the Work

The aim of this study was:

- ❖ To investigate the role of infection as a cause of carcinogenesis by estimating the incidence of anti-cytomegalovirus IgG antibodies in breast cancer patients.
- ❖ To evaluate the use of matrix metalloproteinase-13 as a potential tumor marker in breast cancer.

Chapter I

Introduction

Breast cancer is the most common non-skin cancer amongst women worldwide and is the fifth leading cause of cancer-related mortality overall. Worldwide, breast cancer is the deadliest cancer amongst females in developing countries, causing about half a million total deaths each year (*Power et al., 2018*). Considerations which influence the risk of developing breast cancer include age, race, family history, genetics, lifestyle, and hormonal factors.

Factors that are associated with an increased risk of breast cancer include: being female, increasing age, a personal history of breast conditions, a family history of breast cancer, exposure to radiation, obesity and post-menopausal hormone therapy (*Noor et al., 2016*).

The development of breast cancer occurs as a result of numerous internal and external factors. Recently, the role of infection during carcinogenesis has been studied in several types of oncological diseases. Human herpesvirus is known for its oncogenic potential. Cytomegalovirus (CMV) and Epstein bar virus (EBV) of the *Herpesviridae* family have been implicated as a cause of breast cancer. Recent studies have detected high antibody titer of CMV in patients newly diagnosed with breast cancer (*Mohamed et al., 2014*).

A test for tumor markers is the most convenient method to screen for breast cancer. However, the tumor markers that are currently available for breast cancer